| 0.2479 -0.095 (-27.68%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.06 | 1-year : | 0.09 |
| Resists | First : | 0.05 | Second : | 0.07 |
| Pivot price | 0.02  |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0.02  |
MA(20) : | 0.02 |
| MA(100) : | 0.29 |
MA(250) : | 0.8 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.5 |
D(3) : | 27.4 |
| RSI | RSI(14): 39.8 |
|||
| 52-week | High : | 2.3 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NTBL ] has closed above bottom band by 46.1%. Bollinger Bands are 80.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.06 - 0.06 | 0.06 - 0.06 |
| Low: | 0.02 - 0.02 | 0.02 - 0.02 |
| Close: | 0.02 - 0.02 | 0.02 - 0.02 |
Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.
Tue, 15 Oct 2024
Notable Labs files for bankruptcy, board resigns - Investing.com
Fri, 20 Sep 2024
Cancer-focused biotech Notable Labs lays off 65% of workforce - The Business Journals
Mon, 26 Aug 2024
Notable Labs Announces CEO Transition - GlobeNewswire
Wed, 24 Jul 2024
Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study - GlobeNewswire
Fri, 12 Apr 2024
Notable Labs Reports 2023 Financial Results and Provides a Business Update - GlobeNewswire
Tue, 09 Apr 2024
Notable Labs Presents the Design Plan for the PPMP-Enabled - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 2.07e+006 (%) |
| Held by Institutions | 32.9 (%) |
| Shares Short | 510 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.512e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -269 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | -106.1 % |
| Qtrly Rev. Growth | 313000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 501990 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|